Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 11781134 Targeted RNA editing

Patent 11781134 was granted and assigned to ProQR Therapeutics on October, 2023 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
Current Assignee
ProQR Therapeutics
ProQR Therapeutics
Date Filed
March 3, 2020
Date of Patent
October 10, 2023
Patent Applicant
ProQR Therapeutics
ProQR Therapeutics
Patent Application Number
16807577
Patent Citations
‌
US Patent 11274300 Oligonucleotide complexes for use in RNA editing
‌
US Patent 9650627 Site-directed RNA editing
‌
US Patent 10676737 Targeted RNA editing
‌
US Patent 10941402 Chemically modified single-stranded RNA-editing oligonucleotides
‌
US Patent 10988763 Single-stranded RNA-editing oligonucleotides
‌
US Patent 11390865 Method for introducing site-directed RNA mutation, target editing guide RNA used in the method and target RNA-target editing guide RNA complex
Patent Inventor Names
Bart Klein
Gerardus Johannes Platenburg
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
11781134
Patent Primary Examiner
‌
Brian Whiteman

Find more entities like US Patent 11781134 Targeted RNA editing

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.